Akari Therapeutics (AKTX) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Maxim Group | Upgraded | Hold → Buy | $30.00 | Jul 20, 2026 |
| Maxim Group | Downgraded | Buy → Hold | — | Apr 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $27.00 from $1.60 | Apr 1, 2026 |
| Ladenburg Thalmann | Initiated Coverage | Buy | $1.00 | Jan 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $1.60 | Sep 9, 2025 |
| Maxim Group | Initiated Coverage | Buy | $5.00 | Jul 18, 2025 |
Frequently asked questions
Is AKTX a buy, sell, or hold?
Analysts covering Akari Therapeutics currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on AKTX?
On Jul 20, 2026, Maxim Group upgraded Akari Therapeutics to Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.